Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients.

MLA

Giunta, Emilio Francesco, et al. “Correlation of [68Ga]Ga-PSMA PET/CT Response and PSA Decline in First-Line Enzalutamide for Metastatic Castration-Resistant Prostate Cancer Patients.” European Journal of Nuclear Medicine & Molecular Imaging, vol. 52, no. 1, Dec. 2024, pp. 326–34. EBSCOhost, https://doi.org/10.1007/s00259-024-06887-4.

APA

Giunta, E. F., Caroli, P., Scarpi, E., Altavilla, A., Rossetti, V., Marini, I., Celli, M., Casadei, C., Lolli, C., Schepisi, G., Bleve, S., Brighi, N., Cursano, M. C., Paganelli, G., Matteucci, F., & De Giorgi, U. (2024). Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients. European Journal of Nuclear Medicine & Molecular Imaging, 52(1), 326–334. https://doi.org/10.1007/s00259-024-06887-4

Chicago

Giunta, Emilio Francesco, Paola Caroli, Emanuela Scarpi, Amelia Altavilla, Virginia Rossetti, Irene Marini, Monica Celli, et al. 2024. “Correlation of [68Ga]Ga-PSMA PET/CT Response and PSA Decline in First-Line Enzalutamide for Metastatic Castration-Resistant Prostate Cancer Patients.” European Journal of Nuclear Medicine & Molecular Imaging 52 (1): 326–34. doi:10.1007/s00259-024-06887-4.